Venus Medtech Hangzhou Inc represents a strong set of values and corporate philosophy. With a focus on innovation and patient-centered care, the company strives to provide cutting-edge medical solutions. Venus Medtech Hangzhou Inc prioritizes quality, integrity, and transparency in all aspects of its business operations. With a passionate commitment to improving patient outcomes, the company nurtures a culture of excellence and collaboration. Venus Medtech Hangzhou Inc continuously advances its research and development efforts to create revolutionary cardiovascular technologies. As a result, the company has gained recognition for its dedication to harnessing the power of science and technology to enhance healthcare globally.

Venus Medtech Hangzhou Inc is primarily present in China, where it is headquartered in Hangzhou City, Zhejiang Province. As a leading medical technology company, Venus Medtech has established a strong presence in various Chinese provinces and regions, including Beijing, Shanghai, Guangdong, and Jiangsu. With its innovative cardiac valve products and advanced medical solutions, Venus Medtech is also expanding its footprint globally. The company has successfully expanded into international markets such as Europe, especially in Germany, France, Italy, and the United Kingdom. Venus Medtech Hangzhou Inc continues to strive for further global expansion and enhancing patient care worldwide.

Venus Medtech Hangzhou Inc has achieved several significant milestones. The company successfully developed and commercialized the Venus A-valve, a transcatheter aortic valve implantation (TAVI) system. This innovative product has revolutionized the treatment of aortic valve diseases, providing a less invasive option for patients. Venus Medtech also obtained the CE mark and the Chinese FDA approval for the Venus A-valve, expanding its market reach. The company's dedication to research and development led to the successful completion of clinical trials and collaborations with renowned medical institutions worldwide. With these achievements, Venus Medtech Hangzhou Inc has positioned itself as a global leader in cardiovascular medical devices.

Venus Medtech Hangzhou Inc is a leading medical device company specializing in innovative heart valve technologies. Established in Hangzhou, China, the company has a rich history of continuous improvement and breakthroughs in the field of cardiovascular health. Founded in [year], Venus Medtech has become a prominent player in the global medical device industry, providing life-saving solutions for patients with heart valve diseases. They are renowned for their expertise in transcatheter aortic valve replacement (TAVR) therapies, offering cutting-edge products that ensure improved clinical outcomes. With a strong commitment to research and development, Venus Medtech Hangzhou Inc has emerged as a trusted name in the global healthcare sector, revolutionizing the treatment of heart diseases.

The main competitors of Venus Medtech Hangzhou Inc in the market are company A, company B, and company C.

Venus Medtech Hangzhou Inc is primarily active in the medical equipment industry. They specialize in developing and manufacturing innovative heart valve products, aiming to provide better treatment options for patients suffering from heart valve diseases. With their advanced technology and expertise in the field, Venus Medtech is committed to improving the quality of life for individuals in need of heart valve therapies. Their dedication to this industry has made them a leading company in the medical equipment market, continuously pushing boundaries and driving advancements in heart valve treatment solutions.

Venus Medtech Hangzhou Inc operates under the business model of developing and commercializing medical devices for the treatment of structural heart diseases. Their focus is on the design, production, and distribution of transcatheter heart valve replacement systems. Venus Medtech strives to provide innovative and high-quality solutions that improve patient outcomes and enhance the quality of life for individuals with cardiovascular conditions. Through their commitment to research and development, clinical trials, and strategic partnerships, Venus Medtech aims to revolutionize the treatment options available for structural heart diseases.

Venus Medtech Hangzhou KGV ir -4,96.

Venus Medtech Hangzhou KUV ir 3,90.

AlleAktien kvalitātes vērtējums Venus Medtech Hangzhou ir 4/10.

gaidāmā Venus Medtech Hangzhou apgrozījums ir 579,00 milj. CNY.

gaidāmā Venus Medtech Hangzhou peļņa ir -454,33 milj. CNY.

Venus Medtech Hangzhou Inc is a Chinese medical technology company that specializes in the development, manufacturing, and marketing of minimally invasive devices and products for cardiovascular diagnostics and intervention. The company offers a wide range of products, including coronary stents, peripheral stents, embolization materials, and transcatheter heart valves. Venus Medtech is a leading provider of coronary stents in China and has a growing presence internationally. The company has developed patented technologies to ensure improved performance and safety of their stents. They have also leveraged their expertise in minimally invasive procedures to develop a range of products for transkatheter heart valves. Additionally, Venus Medtech offers embolization therapy products for blocking blood vessels in various medical conditions. They work closely with leading clinics and specialists in the field of minimally invasive procedures and are dedicated to providing innovative technologies and products to meet the needs of their customers and patients. The company also provides training programs for medical professionals and has an active research and development department focused on advancing minimally invasive medicine. In summary, Venus Medtech Hangzhou Inc is a leading provider of minimally invasive devices and products for cardiovascular diagnostics and intervention, with a wide product range, patented technologies, and a dedicated research and development team.

Venus Medtech Hangzhou izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Venus Medtech Hangzhou vai uzņēmums nedod dividendes.

Venus Medtech Hangzhou ISIN ir CNE100003PJ8.

Venus Medtech Hangzhou simbols ir 2500.HK.

Pēdējo 12 mēnešu laikā Venus Medtech Hangzhou maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Venus Medtech Hangzhou plāno maksāt dividendes 0 CNY apmērā.

Venus Medtech Hangzhou pašreizējā dividendu rentabilitāte ir .

Venus Medtech Hangzhou maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Venus Medtech Hangzhou pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

Venus Medtech Hangzhou tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Venus Medtech Hangzhou apmērā 0 CNY, kas tika izmaksāta 3.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.11.2024..

Pēdējās dividendes izmaksa notika 3.11.2024..

Gadā 2023, Venus Medtech Hangzhou izmaksāja 0 CNY dividendes.

Venus Medtech Hangzhou dividendes tiek izmaksātas CNY.